Tradestie Institutional Equity Comparison Engine · Market Close May 08, 2026

AVDL vs KZR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–1 Matrix Metrics)

AVDL Overall Winner 6-Pillar Tally: AVDL 4 – 1 KZR (1 Tie) Matrix Metrics: AVDL 8 – 1 KZR

As of May 08, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Kezar Life Sciences, Inc. (KZR) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas KZR carries 60.1/100 (BUY) at $7.29 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs KZR
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
KZR NASDAQ
Kezar Life Sciences, Inc. Common Stock
Pharmaceutical Preparations
$7.29
-0.95% 1D
Market Cap $54.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.60β · 8% Vol
Unified Composite Score
60.1 / 100 BUY
Tech 40.0 Fund 51.0 Flow 56.0 Mom 58.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.7% over 20 days), RSI 53
RSI-14: 52.6 · SMA20: $7.33 · SMA50: $7.12

6-Pillar Scorecard Institutional Category Breakdown (AVDL 4 – 1 KZR)

Columns: Metric · AVDL · KZR
1. Valuation Multiples AVDL
Forward P/E 28.8x N/M
Trailing P/E 16.8x N/M
PEG Ratio 0.07x N/M
EV / Revenue 8.5x N/M
2. Growth & Scale AVDL
Revenue Growth (YoY) +54.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $249M N/A
Market Cap $2.1B $54.4M
3. Profitability & Quality AVDL
Gross Margin 94.9% N/A
Operating Margin 2.5% 0.0%
Net Profit Margin -0.1% 0.0%
Return on Equity (ROE) -0.3% -59.9%
4. Balance Sheet & Cash Flow AVDL
Cash Generation (TTM) $2.7M EBITDA N/A
Cash Flow Margin 1.1% EBITDA Mgn N/A
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE $9.56 Book/Sh · -59.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KZR
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 2.4% (<1st %ile) 37.2% (9th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (8) vs KZR (1)
Institutional Metric AVDL KZR Criterion Row Edge
Market Capitalization
Scale
$2.1B $54.4M Larger Scale AVDL
Trailing P/E Ratio
Valuation
16.8x N/M Lower Multiple AVDL
Forward P/E Ratio
Valuation
28.8x N/M Lower Multiple AVDL
Revenue Growth (YoY)
Growth
+54.9% +0.0% Higher Growth AVDL
Operating Margin (TTM)
Profitability
2.5% 0.0% Higher Margin AVDL
Net Profit Margin
Profitability
-0.1% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-0.3% -59.9% Higher ROE AVDL
52-Week Range Position
Momentum
89% ($6–$24) 94% ($4–$8) Stronger Trend KZR
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 0.60β · 8% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 60.1 / 100 (BUY) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) N/A ($9.56 Book/Sh · -59.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KZR +2.61 pp
AVDL: +0.65% · KZR: +3.26%
3M Horizon AVDL +13.3 pp
AVDL: +15.72% · KZR: +2.42%
6M Horizon KZR +1.07 pp
AVDL: +61.49% · KZR: +62.56%
1Y Horizon AVDL +73.12 pp
AVDL: +128.51% · KZR: +55.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs KZR. Trailing 12-month operating profitability (AVDL 2.5% vs KZR 0.0%) and valuation multiples (AVDL 28.8x vs KZR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
KZR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-59.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KZR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 37.2%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact KZR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KZR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $54.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs KZR Key Questions & Quantitative Answers

As of May 08, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Kezar Life Sciences, Inc. (KZR) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas KZR carries 60.1/100 (BUY) at $7.29 (N/M Forward P/E, 0.0% operating margin). Technically, AVDL sits in a Markup phase (RSI 62.3, UNCLASSIFIED options structure) and KZR sits in a Markup phase (RSI 52.6, UNCLASSIFIED options structure).

AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with KZR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus N/A for KZR. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KZR.

AVDL screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas KZR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus KZR (-59.9% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, KZR carries 37.2% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.60β · 8% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 08, 2026. For educational research only; not investment advice.